Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Tiziana Life Sciences ( (TLSA) ) is now available.
On September 9, 2025, Tiziana Life Sciences announced that CEO Ivor Elrifi purchased 14,848 shares of the company’s common stock at $1.65 per share, bringing his total holdings to 193,848 shares. This move underscores confidence in the company’s strategic direction, particularly its focus on developing intranasal foralumab, which is currently undergoing clinical trials for treating non-active secondary progressive multiple sclerosis. The announcement may positively impact stakeholder perceptions and signals strong internal belief in Tiziana’s innovative approach to immunotherapy.
The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using transformational drug delivery technologies. The company specializes in immunomodulation therapies, with its lead candidate being intranasal foralumab, a fully human anti-CD3 monoclonal antibody. Tiziana aims to improve efficacy, safety, and tolerability of treatments through innovative nasal delivery methods, targeting neuroinflammatory and neurodegenerative diseases.
Average Trading Volume: 345,441
Technical Sentiment Signal: Buy
Current Market Cap: $185M
Learn more about TLSA stock on TipRanks’ Stock Analysis page.